Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
BLUE > SEC Filings for BLUE > Form 8-K on 13-Jan-2014All Recent SEC Filings

Show all filings for BLUEBIRD BIO, INC. | Request a Trial to NEW EDGAR Online Pro

Form 8-K for BLUEBIRD BIO, INC.


13-Jan-2014

Change in Directors or Principal Officers, Regulation FD Disclosure, Financial


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On January 7, 2014, Dr. Axel Polack notified bluebird bio, Inc. (the "Company") of his resignation from the Company's board of directors (the "Board"), effective immediately. Dr. Polack's resignation was not caused by any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

On January 8, 2014, the Board, upon the recommendation of the Company's corporate governance and nominating committee, elected James Mandell, M.D. to the Board to fill the newly-created vacancy. In connection with his election, on January 8, 2014, the Company granted Dr. Mandell a stock option to purchase 20,000 shares of common stock with an exercise price of $21.43, the closing price of the Company's common stock on the Nasdaq Global Market on January 8, 2014.

Dr. Mandell is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K, and there are no arrangements or understandings between Dr. Mandell and any other persons pursuant to which he was selected as a director. Dr. Mandell has not yet been appointed to serve on any committee of the Board. Information concerning the membership of the Board's committees is publicly available on the Company's website at http://www.bluebirdbio.com. The Company intends to disclose changes in the membership of committees of the Board by posting this information on its website and/or in its public filings with the Securities and Exchange Commission.



Item 7.01 Regulation FD Disclosure

On January 9, 2014, the Company issued a press release announcing Dr. Mandell's appointment to the Board. A copy of this press release is furnished as Exhibit 99.1 to this report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.



Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit
  No.        Description

99.1         Press release issued by bluebird bio, Inc. on January 9, 2014,
             furnished herewith.


  Add BLUE to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for BLUE - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.